Edgewise Therapeutics (EWTX) Competitors $14.48 -0.19 (-1.26%) As of 11:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. RNA, CYTK, AXSM, NUVL, TGTX, MRUS, CRSP, PTCT, KRYS, and PCVXShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Avidity Biosciences (RNA), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), Nuvalent (NUVL), TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Its Competitors Avidity Biosciences Cytokinetics Axsome Therapeutics Nuvalent TG Therapeutics Merus CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte Avidity Biosciences (NASDAQ:RNA) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations. Do analysts recommend RNA or EWTX? Avidity Biosciences presently has a consensus target price of $68.33, indicating a potential upside of 55.36%. Edgewise Therapeutics has a consensus target price of $40.55, indicating a potential upside of 179.91%. Given Edgewise Therapeutics' higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.06Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91 Which has higher earnings & valuation, RNA or EWTX? Edgewise Therapeutics has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.73M527.41-$322.30M-$3.56-12.35Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-9.35 Does the media refer more to RNA or EWTX? In the previous week, Avidity Biosciences had 23 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 31 mentions for Avidity Biosciences and 8 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.72 beat Avidity Biosciences' score of 0.78 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 15 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is RNA or EWTX more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -4,247.77%. Edgewise Therapeutics' return on equity of -30.65% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,247.77% -33.45% -30.22% Edgewise Therapeutics N/A -30.65%-29.18% Which has more risk & volatility, RNA or EWTX? Avidity Biosciences has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. SummaryEdgewise Therapeutics beats Avidity Biosciences on 8 of the 13 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$3.18B$5.80B$10.16BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-9.3421.4874.7325.99Price / SalesN/A301.34470.3491.76Price / CashN/A45.3337.0859.91Price / Book2.999.6312.256.31Net Income-$133.81M-$53.32M$3.28B$270.66M7 Day Performance-6.97%0.95%1.39%3.52%1 Month Performance8.18%9.68%7.70%6.79%1 Year Performance-17.56%13.38%64.01%28.29% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics2.8254 of 5 stars$14.49-1.3%$40.55+179.9%-12.9%$1.53BN/A-9.3460Positive NewsRNAAvidity Biosciences2.127 of 5 stars$48.05-4.6%$67.00+39.4%+1.2%$6.48B$10.73M-13.50190News CoverageAnalyst ForecastInsider TradeGap UpCYTKCytokinetics4.3293 of 5 stars$52.09-1.7%$75.38+44.7%-0.8%$6.34B$18.47M-10.21250Insider TradeAXSMAxsome Therapeutics4.9162 of 5 stars$129.29+3.3%$177.86+37.6%+35.1%$6.25B$385.69M-25.50380Positive NewsInsider TradeNUVLNuvalent3.0322 of 5 stars$79.83-1.3%$120.91+51.5%-4.0%$5.83BN/A-16.2940Positive NewsTGTXTG Therapeutics4.1683 of 5 stars$32.38+0.5%$46.25+42.8%+40.7%$5.11B$329M87.51290Positive NewsMRUSMerus2.9344 of 5 stars$67.19-0.4%$88.75+32.1%+38.8%$5.10B$36.13M-12.2237Positive NewsCRSPCRISPR Therapeutics3.3247 of 5 stars$54.10-1.4%$71.60+32.3%+23.0%$4.99B$37.31M-9.96460PTCTPTC Therapeutics3.6468 of 5 stars$56.95-0.5%$69.00+21.2%+88.9%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.942 of 5 stars$145.20-3.4%$210.38+44.9%-27.4%$4.35B$290.52M29.51210Positive NewsPCVXVaxcyte2.2918 of 5 stars$32.41-1.8%$130.00+301.1%-70.9%$4.29BN/A-7.89160Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Avidity Biosciences Competitors Cytokinetics Competitors Axsome Therapeutics Competitors Nuvalent Competitors TG Therapeutics Competitors Merus Competitors CRISPR Therapeutics Competitors PTC Therapeutics Competitors Krystal Biotech Competitors Vaxcyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EWTX Stock Alerts